Linezolid Krka (Linezolid)

Linezolid is used to treat serious Gram‑positive bacterial infections, particularly those resistant to other antibiotics.

• Complicated skin and soft tissue infections: provides effective therapy against susceptible Gram‑positive organisms, including MRSA, reducing tissue damage and systemic spread.
• Community‑acquired bacterial pneumonia: eradicates the causative pathogens, improving respiratory function and shortening hospital stay.
• Nosocomial pneumonia: targets hospital‑acquired strains resistant to β‑lactams, aiding recovery in intensive care settings.
• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers a reliable option when vancomycin is unsuitable or ineffective.
• Vancomycin‑resistant Enterococcus (VRE) infections: delivers bacteriostatic activity against resistant enterococci, supporting infection control.

• Linezolid binds to the 50S subunit of bacterial ribosomes, preventing formation of the initiation complex required for protein synthesis. By blocking the early stage of translation, it halts bacterial growth without affecting human ribosomes, resulting in a bacteriostatic effect against most susceptible Gram‑positive organisms, including MRSA and VRE. The interaction is reversible and does not interfere with DNA replication, making the drug selective for bacterial cells.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate feeling of stomach upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Rash: skin redness or mild itching.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count, increasing bleeding risk.
• Peripheral neuropathy: nerve pain or sensory loss, potentially irreversible.
• Serotonin syndrome: hyperthermia, agitation, and autonomic instability when combined with serotonergic drugs.
• Optic neuropathy: visual disturbances that may affect acuity.

Before initiating Linezolid therapy, clinicians should consider several safety precautions to minimize risks.

• Monitor blood counts: perform baseline and periodic CBC to detect thrombocytopenia or anemia.
• Assess renal function: adjust therapy in patients with severe impairment and monitor for accumulation.
• Evaluate for serotonergic drug use: avoid concurrent MAO inhibitors or SSRIs to prevent serotonin syndrome.
• Use cautiously in patients with a history of myelosuppression: consider alternative agents if prior bone‑marrow toxicity.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several medicines; awareness of these interactions helps ensure safe co‑administration.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use can cause hypertensive crisis or serotonin syndrome.
• Serotonergic agents (SSRIs, SNRIs, TCAs, tramadol): increase risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Rifampin: induces hepatic enzymes, reducing linezolid plasma concentrations.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Oral contraceptives: linezolid can lower hormonal efficacy, advise additional contraceptive measures.